JP2023533218A5 - - Google Patents
Info
- Publication number
- JP2023533218A5 JP2023533218A5 JP2022580159A JP2022580159A JP2023533218A5 JP 2023533218 A5 JP2023533218 A5 JP 2023533218A5 JP 2022580159 A JP2022580159 A JP 2022580159A JP 2022580159 A JP2022580159 A JP 2022580159A JP 2023533218 A5 JP2023533218 A5 JP 2023533218A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- cancer
- compound according
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043771P | 2020-06-24 | 2020-06-24 | |
| US63/043,771 | 2020-06-24 | ||
| PCT/US2021/038781 WO2021262910A2 (en) | 2020-06-24 | 2021-06-23 | Tubulysins and protein-tubulysin conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533218A JP2023533218A (ja) | 2023-08-02 |
| JP2023533218A5 true JP2023533218A5 (enExample) | 2024-07-04 |
Family
ID=76959103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580159A Pending JP2023533218A (ja) | 2020-06-24 | 2021-06-23 | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230069722A1 (enExample) |
| EP (1) | EP4171653A2 (enExample) |
| JP (1) | JP2023533218A (enExample) |
| KR (1) | KR20230028325A (enExample) |
| CN (1) | CN115867563B (enExample) |
| AU (1) | AU2021296449A1 (enExample) |
| BR (1) | BR112022024361A2 (enExample) |
| CA (1) | CA3185601A1 (enExample) |
| CL (1) | CL2022003715A1 (enExample) |
| CO (1) | CO2022019161A2 (enExample) |
| IL (1) | IL299254A (enExample) |
| MA (1) | MA58646A1 (enExample) |
| MX (1) | MX2022015769A (enExample) |
| PH (1) | PH12023550032A1 (enExample) |
| WO (1) | WO2021262910A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| WO2020132658A2 (en) | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| WO2023129518A1 (en) | 2021-12-29 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| CN116747315A (zh) * | 2023-06-20 | 2023-09-15 | 中国科学院长春应用化学研究所 | 高dar值的抗体-免疫调节药物偶联物及其制备方法和应用 |
| IL325400A (en) | 2023-07-10 | 2026-02-01 | Regeneron Pharma | Anti-human CACNG1 antibody-drug conjugates and their uses |
| IL327670A (en) | 2023-10-11 | 2026-06-01 | Antikor Biopharma Ltd | Antibodies, conjugates, and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| US20080305044A1 (en) | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2148886B1 (en) * | 2007-05-10 | 2014-02-19 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| EP2209374B1 (en) * | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysins and processes for preparing |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| PL2872157T3 (pl) * | 2012-07-12 | 2020-07-13 | Hangzhou Dac Biotech Co., Ltd | Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| DK2935331T3 (en) * | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| DK2956173T3 (en) * | 2013-02-14 | 2017-07-17 | Bristol Myers Squibb Co | TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2015113760A1 (en) * | 2014-01-28 | 2015-08-06 | Tube Pharmaceuticals Gmbh | Cytotoxic tubulysin compounds for conjugation |
| CA2945318A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| HRP20241124T1 (hr) * | 2014-09-11 | 2024-11-22 | Seagen Inc. | Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin |
| US10077287B2 (en) * | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| CA3012960A1 (en) * | 2016-02-01 | 2017-08-10 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| EP3419670A2 (en) * | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| JP2019518013A (ja) * | 2016-05-10 | 2019-06-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 安定性が向上したツブリシン類似体の抗体薬物結合体 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| CA3247730A1 (en) * | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| WO2020132658A2 (en) * | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| JP2022544442A (ja) * | 2019-06-24 | 2022-10-19 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | チューブリシン類縁体と細胞結合分子との共役体の製剤 |
| CA3166619A1 (en) * | 2020-02-28 | 2021-09-02 | Julian Andreev | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
-
2021
- 2021-06-23 MX MX2022015769A patent/MX2022015769A/es unknown
- 2021-06-23 IL IL299254A patent/IL299254A/en unknown
- 2021-06-23 KR KR1020227046382A patent/KR20230028325A/ko active Pending
- 2021-06-23 BR BR112022024361A patent/BR112022024361A2/pt unknown
- 2021-06-23 EP EP21742993.5A patent/EP4171653A2/en active Pending
- 2021-06-23 PH PH1/2023/550032A patent/PH12023550032A1/en unknown
- 2021-06-23 US US17/356,497 patent/US20230069722A1/en active Pending
- 2021-06-23 CA CA3185601A patent/CA3185601A1/en active Pending
- 2021-06-23 AU AU2021296449A patent/AU2021296449A1/en active Pending
- 2021-06-23 MA MA58646A patent/MA58646A1/fr unknown
- 2021-06-23 JP JP2022580159A patent/JP2023533218A/ja active Pending
- 2021-06-23 CN CN202180044933.9A patent/CN115867563B/zh active Active
- 2021-06-23 WO PCT/US2021/038781 patent/WO2021262910A2/en not_active Ceased
-
2022
- 2022-12-22 CL CL2022003715A patent/CL2022003715A1/es unknown
- 2022-12-28 CO CONC2022/0019161A patent/CO2022019161A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020263231B2 (en) | Camptothecin derivatives | |
| CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| JP7617974B2 (ja) | シクロデキストリンタンパク質薬物コンジュゲート | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP7798998B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| JP2023105175A (ja) | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 | |
| TWI877186B (zh) | 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途 | |
| CN107614488B (zh) | 新型亲水连接体和其在配体-药物共轭偶联物上的应用 | |
| CN110392685B (zh) | 苯并二氮卓衍生物的选择性磺化 | |
| ES2722103T9 (es) | Agentes citotóxicos bifuncionales | |
| TW201838657A (zh) | 具有自分解肽連接子之類美登素衍生物及其結合物 | |
| JP7854462B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| CN119095625A (zh) | 抗体-药物偶联物 | |
| CN117750982A (zh) | 偶联试剂及其偶联物 | |
| JP2025539807A5 (enExample) | ||
| CN119156232A (zh) | 抗体-药物偶联物前体及其合成中间体 | |
| JP7667870B2 (ja) | Ｄｎａ毒性二量体及びその複合体 | |
| CA3137125C (en) | Camptothecin derivatives | |
| RU2021134145A (ru) | Производные камптотецина | |
| NZ744373B2 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| NZ744373A (en) | Maytansinoid derivatives, conjugates thereof, and methods of use |